Page 134 - 《中国药房》2026年9期

Devel Ther，2018，12：1525-1531. 1107-1119.
[17] 王丹 . 卡非佐米治疗复发性/难治性多发性骨髓瘤的系 [26] PELLIGRA C G，PARIKH K，GUO S E，et al. Cost-
统评价和Meta分析[D]. 太原：山西医科大学，2019. effectiveness of pomalidomide，carfilzomib，and daratu‐
[18] 徐彪，冉启杰，李菁媛，等. 卡非佐米对复发/难治性多发 mumab for the treatment of patients with heavily pre‐
性骨髓瘤的治疗效果的 Meta 分析[J]. 华南国防医学杂 treated relapsed-refractory multiple myeloma in the
志，2020，34（2）：136-140. United States[J]. Clin Ther，2017，39（10）：1986-2005.e5.
[19] GAY F，GÜNTHER A，OFFIDANI M，et al. Carfilzomib， [27] CAMPIONI M，AGIRREZABAL I，HAJEK R，et al.
bendamustine，and dexamethasone in patients with ad‐ Methodology and results of real-world cost-effectiveness
vanced multiple myeloma：the EMN09 phase 1/2 study of of carfilzomib in combination with lenalidomide and dexa‐
the European Myeloma Network[J]. Cancer，2021，127 methasone in relapsed multiple myeloma using registry
（18）：3413-3421. data[J]. Eur J Health Econ，2020，21（2）：219-233.
[20] VENNER C P，LEBLANC R，SANDHU I，et al. Weekly [28] GOUDARZI Z，SHAHTAHERI R S，NAJAFPOUR Z，
carfilzomib plus cyclophosphamide and dexamethasone et al. Cost-effectiveness and budget impact analysis of
in the treatment of relapsed/refractory multiple myeloma： Daratumumab，Lenalidomide and dexamethasone for
final results from the MCRN-003/MYX. 1 single arm relapsed-refractory multiple myeloma[J]. Cost Eff Resour
phase Ⅱ trial[J]. Am J Hematol，2021，96（5）：552-560. Alloc，2024，22（1）：17.
[21] YONG K L，HINSLEY S，AUNER H W，et al. Carfilzo‐ [29] Austrian Institute for Health Technology Assessment.
mib or bortezomib in combination with cyclophospha‐ Carfilzomib （Kyprolis ） for patients with relapsed mul‐
®
mide and dexamethasone followed by carfilzomib mainte‐ tiple myeloma who have received one to three prior lines
nance for patients with multiple myeloma after one prior of therapy[EB/OL]. [2025-11-15]. https：//eprints. aihta. at/
therapy：results from a multicenter，phase Ⅱ，randomized， 1070/.
controlled trial （MUKfive）[J]. Haematologica，2021，106 [30] Canada’s Drug and Health Technology Agency. Kyprolis
（10）：2694-2706. for multiple myeloma （relapsed）：details[EB/OL]. [2025-
[22] NINKOVIC S，HARRISON S J，LEE J J，et al. Carfilzo‐ 04-07]. https：//www.cadth.ca/kyprolis-multiple-myeloma-
mib，thalidomide，and dexamethasone are safe and effec‐ relapsed-details.
tive in relapsed and/or refractory multiple myeloma：final [31] National Institute for Health and Care Excellence. Carfil‐
report of the single-arm，multicenter，phase Ⅱ ALLG zomib for previously treated multiple myeloma[EB/OL].
MM018/AMN002 study[J]. Haematologica，2024，109 [2025-04-07]. https：//www.nice.org.uk/guidance/ta657.
（7）：2229-2238. [32] National Institute for Health and Care Excellence. Carfil‐
[23] PERROT A，DELIMPASI S，SPANOUDAKIS E，et al. An zomib with dexamethasone and lenalidomide for pre-
open-label phase 2 study treating patients with first or viously treated multiple myeloma[EB/OL]. [2025-04-07].
second relapse of multiple myeloma with carfilzomib， https：//www.nice.org.uk/guidance/ta695.
pomalidomide，and dexamethasone （KPd）：SELECT [33] PROSKURIAKOVA E，JADA K，KAKIEU DJOSSI S，
study[J]. Leuk Lymphoma，2024，65（6）：833-842. et al. Mechanisms and potential treatment options of heart
[24] JAKUBOWIAK A J，CAMPIONI M，BENEDICT Á， failure in patients with multiple myeloma[J]. Cureus，
et al. Cost-effectiveness of adding carfilzomib to lenalido‐ 2021，13（6）：e15943.
mide and dexamethasone in relapsed multiple myeloma [34] MINA S A，MUHSEN I N，BURNS E A，et al. Post-
from a US perspective[J]. J Med Econ，2016，19（11）： marketing analysis of peripheral neuropathy burden with
1061-1074. new-generation proteasome inhibitors using the FDA ad‐
[25] JAKUBOWIAK A J，HOUISSE I，MÁJER I，et al. Cost- verse event reporting system[J]. Turk J Haematol，2021，38
effectiveness of carfilzomib plus dexamethasone com‐ （3）：218-221.
pared with bortezomib plus dexamethasone for patients （收稿日期：2025-10-13 修回日期：2026-03-25）
with relapsed or refractory multiple myeloma in the （编辑：刘明伟）
United States[J]. Expert Rev Hematol，2017，10（12）：

· 1228 · China Pharmacy 2026 Vol. 37 No. 9 中国药房 2026年第37卷第9期